Functional defects of the mitochondrial translation machinery, as a result of mutations in nuclear-encoded genes, have been associated with combined oxidative phosphorylation (OXPHOS) deficiencies. We report siblings with congenital sensorineural deafness and lactic acidemia in association with combined respiratory chain (RC) deficiencies of complexes I, III and IV observed in fibroblasts and liver. One of the siblings had a more severe phenotype showing progressive hepatic and renal failure. Wholeexome sequencing revealed a homozygous mutation in the gene encoding mitochondrial ribosomal protein S7 (MRPS7), a c.550A>G transition that encodes a substitution of valine for a highly conserved methionine ( p.Met184Val) in both affected † These authors contributed equally to this research.
Introduction
The mitochondrial translation machinery consists of tRNA, rRNA and various RNA processing enzymes and translation initiation, elongation and termination factors, as well as ribosomal recycling proteins (1, 2) . The proper functioning of all these components of the mitochondrial translation machinery is required for the synthesis of the 13 mitochondrial-encoded respiratory chain (RC) complex subunits. Mutations in genes required for this complex process result in a range of diseases (3) , and often lead to combined RC enzyme deficiencies (1, 4) . The mammalian mitochondrial ribosome is composed of small (28 S) and large (39 S) subunits (5) . 12S rRNA along with 30 proteins, form the small 28 S subunit, whereas the 16S rRNA and 48 proteins form the large 39 S subunit (1, 5) . MRPS7 is a small subunit mitochondrial ribosomal protein (MRP) located at the region of the 28 S subunit known to interact with the 12S rRNA, and is the only RNA-binding protein in this region of the crystal structure (5) .
All MRP subunits are nuclear-encoded (6) and of the 80 proteins in total, only 4 have been associated with mitochondrial disorders. Mutations in MRPS22 (OMIM 605810) (7, 8) and MRPS16 (OMIM 609204) (9) that encode protein subunits from the small 28 S subunit, and MRPL3 (OMIM 607118) (10) , MRPL12 (OMIM 602375) (4) and MRPL44 (OMIM 611849) (11) that encode subunits from the large 39 S subunit, have been reported to cause combined RC enzyme deficiencies. The clinical phenotypes associated with mutations in MRPs are highly heterogeneous. The p.Arg170His variation in MRPS22 led to generalized edema and ascites, hypotonia, cardiomyopathy and tubulopathy (8) , whereas a p.Leu215Pro variation in the same protein resulted in Cornelia de Lange-like dysmorphic features in another family (7) . The p.Arg111* variation in MRPS16, resulting in premature truncation, was found to cause lactic acidemia, agenesis of the corpus callosum and facial dysmorphism in the affected family (9) . The mitochondrial translation defect caused by the p.Ala181Val variation in MRPL12 led to growth retardation, facial dysmorphism and neurological deterioration (4) . Finally, four siblings presenting with severe infantile onset hypertrophic cardiomyopathy and psychomotor retardation had compound heterozygous mutations in MRPL3 comprising a large 255 kb genomic deletion and an MRPL3 p.Pro317Arg change (10) .
In this study, we report a mutation in MRPS7, encoding the MRP S7, which was identified by whole-exome sequencing (WES) in siblings with congenital sensorineural deafness and significant hepatic and renal impairment. Both siblings had combined RC deficiencies indicative of a primary mitochondrial disorder. A range of functional studies were undertaken to confirm the pathogenicity of the mutation, including its effect on RC function and MRP homeostasis.
Results

Patient clinical information
The Human Research Ethics Committee of the Children's Hospital at Westmead approved this research, and as required by that approval, written consent was obtained from adult family members.
The affected siblings were born to non-consanguineous parents, and presented with congenital sensorineural deafness. Patient 1, the second child, has been previously reported (12) . She was born at term following an uncomplicated pregnancy, with Apgar scores of 7 and 9 at 1 and 5 min, respectively, and had a birth weight of 3640 g (50th percentile). Early neuromotor development was normal except for speech acquisition. However, because of recurrent emesis, she developed a failure to thrive. Investigations at 6 months of age failed to reveal an etiology for the vomiting. Formal audiology assessment revealed profound bilateral sensorineural deafness. At 13 months of age, she underwent electrocochleography and myringotomy, but post-anesthetic began vomiting and became progressively encephalopathic. She was noted at that time to have hepatomegaly, was hypoglycemic (blood glucose <0.5 mmol/l; normal range 2.5-5.5) and had a raised blood lactate (4.1 mmol/l; normal range 0.7-2.0). Resuscitative treatment led to a rapid recovery, with a normal physical examination apart from the hepatomegaly. A CT scan of the head, cardiology and ophthalmology assessment at that time were normal, and urinary organic acids showed a large 3-hydroxybutyrate peak, with lesser elevations of lactate, fumarate and C6-C10 dicarboxylic acids. Urinary acylglycines were normal, as were liver and renal function. Subsequent fibroblast fatty acid oxidation studies, screening for the common ACADM p.Lys304Glu mutation, and provocative testing for glycogen storage disorders were all normal. She subsequently went on to have a cochlear implant with satisfactory acquisition of speech.
Because of persistent hepatomegaly and lactic acidemia, she went on to have muscle, liver and skin biopsies at the age of 2 years. Liver histology showed marked steatosis, mild fibrous expansion of portal tracts but no glycogen accumulation. Muscle showed an increase in the size of lipid droplets, no glycogen accumulation, a normal checkerboard appearance and normal immunohistochemical staining for SDH, LDH, NADH-TR and COX.
Spectrophotometric RC enzyme studies showed that she had severe complexes I, III and IV deficiency in the liver, but normal activities in skeletal muscle for all complexes except complex III, which was mildly reduced in Patient 1 (Table 1) . RC enzyme activity in fibroblasts using dipstick enzyme assays showed a clear reduction in complexes I and IV activities (Fig. 3B) .
At the age of 4½ years, her motor and cognitive development was normal. However, she was lost to follow up for a number of years, and she represented at the age of 14 years with fever, liver failure, abdominal distension and pain, which was presumed to be due to acute bacterial peritonitis (although an organism was not identified), and she was also found to have pancytopenia and renal dysfunction. She improved with resuscitative treatments, antibiotics (gentamicin and vancomycin) and nasogastric feeds were commenced to renourish her in preparation for transplantation. However, 4 weeks after her presentation with this illness, her liver failure worsened as did her renal function, ultimately requiring hemofiltration. She became encephalopathic (normal blood ammonium) and ventilator-dependent. A CT scan of the head and cerebral perfusion scan were indicative of a left parieto-occipital infarct, which rendered her ineligible for liver transplant. With parental consent intensive support was withdrawn, and she died at the age of 14 years 5 months. Post-mortem was declined.
Liver mitochondrial DNA to nuclear DNA (mtDNA:nDNA) ratios were found to be slightly elevated. This could be related to the high citrate synthase activity in the liver of both patients (Table 1 ). These two observations suggest an increase in the mitochondrial mass. Screening for common mtDNA point mutations, sequencing of the tRNA leu(UUR) gene and southern analysis for large deletions or duplications were all normal. Patient 2, the fourth child, was born at term following an uncomplicated delivery, and was found to have profound congenital bilateral sensorineural deafness, with electrocochleograms showing near total loss of sensory function in both cochleae. She had intermittently elevated blood lactate in early childhood, but more recently, this has mostly been in the normal range. She was prone to episodes of hypoglycemia in her early childhood years, but this subsequently resolved spontaneously. She went on to have a cochlear implant without incident. She had mild learning difficulties throughout childhood. Because of failure of pubertal development she was investigated at the age of 16 years and found to have primary hypogonadism, and despite being clinically euthyroid, her TSH was mildly elevated (6.75 mIU/l; normal range 0.4-4.2), while the rest of her thyroid function tests were normal, and a short synacthen test was indicative of primary adrenal failure. She was placed on estrogen hormonal replacement with good effect and low-dose hydrocortisone replacement therapy.
When last reviewed at age 17½ years, she was generally well. Her weight was 42.6 kg (1st percentile), and height was 153.8 cm (8th percentile). Cardiovascular, respiratory and neurological examinations, apart from hearing, were normal. Abdominal examination revealed no hepatosplenomegaly, or any signs of chronic liver disease. Her serum urea (9.4 mmol/l; normal range 2.0-6.8) and creatinine (158 µmol/l; normal range 31-87) were elevated, as was the blood lactate (2.5 mmol/l), but liver function and coagulation studies were normal.
She had a muscle and liver biopsy at 6 months of age. Liver histology showed a mild increase in spaces of Disse, extending in the portal areas. Hepatocytes were swollen and there was mild steatosis. Glycogen stores were not increased, and there was grade 1-2 iron accumulation. Muscle histology showed mild type 1 fibre predominance, and oxidative stains were unremarkable. Muscle and liver RC enzymology showed similar results to those of her older sister (Table 1) .
A renal biopsy at 13 years of age showed that the glomeruli generally had a normal appearance, with many renal tubules containing protein casts, and were somewhat atrophic and dilated by giant mitochondria up to 5.5 μm in diameter (normal size 0.5-1.0 μm), with most having increased mitochondrial matrix and reduced cristae, while a few had abundant cristae, but no paracrystalline arrays or other mitochondrial inclusions (Supplementary Material, Fig. S1 ).
The parents, their first child, a girl, and the third child, a boy, were all healthy with normal auditory, liver and renal function, and no other significant health problems.
WES identified a homozygous MRPS7 mutation
We performed WES on the proband (P1), her affected sister (P2), an unaffected sister (S1) and both unaffected parents (S2 and S3), with each individual's exome covered at least 54 times (Supplementary Material, Table S1 ). A large number of variants and insertions/deletions (indels) were called (Supplementary Material, Table S1 ) and after filtering through two different pipelines (see Supplementary Materials and Methods), and assuming an autosomal-recessive mode of inheritance, a list of candidate genes was generated (Supplementary Material, Table S2 ). One non-synonymous mutation in the MRPS7 gene (rs115047866, c.550A>G, p.Met184Val, OMIM 611974) was identified through CAG and BGI bioinformatics screening of the raw exome data. The affected siblings were found to be homozygous for the c.550A>G variant, whereas the parents and unaffected sister were heterozygous for the variation (Fig. 1A) . The variation was confirmed by Sanger sequencing of the entire family. The c.550A>G mutation has been reported as an SNP (rs115047866) (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=51081), which changes a highly conserved methionine to valine ( p.Met184Val) (Fig. 1B) . This variant is very rare in terms of minor allele frequencies in the public (heterozygosity value of 0.002 in dbSNP) and in-house databases (CAG frequency 0.67%) (Supplementary Material, Table S2 ).
MRPS7 was within a shared region of an ROH
As c.550A>G variant is a rare homozygous variant, investigations were undertaken to infer if there was unrecognized relatedness between the parents. Estimating the genomic segments of regions of homozygosity (ROH; also known as runs of homozygosity or loss of heterozygosity) call showed many (1450) SNPs with homozygosity of a ∼1 Mb region on 17q25.1 including MRPS7 in both affected siblings, but not present in the unaffected family members (Supplementary Material, Fig. S4 ). Referencing a large control cohort (334 unaffected controls) confirmed the presence of an ROH was rare on 17q25.1, and of the few that had ROH, none contained a deleterious homozygous mutation in MRPS7. Therefore, the ROH data indicate the possibility of mere randomness (13), or remotely shared ancestry such as the one that has been observed previously (14) , although there is no evidence of consanguinity in the family history.
In silico analyses suggest the p.Met184Val mutation destabilizes the MRPS7 protein structure
In the three-dimensional model of the wild-type MRPS7 protein, Met184 was at the hydrophobic core of the structure, forming five long-range hydrophobic interactions with five spatially neighboring residues (Val90, Phe94, Met97, Phe145 and Leu149) (Fig. 1C, left) . This number is significantly higher than the average number of favorable interactions per residue reported for soluble proteins (0.60-1.62) (15) , demonstrating the pivotal role of this residue in stabilizing the folded structure. The p.Met184Val mutation resulted in the loss of most of these essential interactions (Fig. 1C, right) , due to the smaller side chain of the valine amino acid. Conservation analysis of the interacting hydrophobic residues, effect of the mutation on the free energy of the protein and disease-association prediction (Supplementary Material and Supplementary Material, Fig. S3 ) together suggest that the p.Met184Val mutation destabilizes the protein.
Reduced MRPS7 levels result in decreased OXPHOS in patient fibroblasts
Functional assays were performed to confirm the deleterious nature of the p.Met184Val MRPS7 mutation. Immunoblot analysis of P1 fibroblasts showed a severe reduction in MRPS7 levels, supporting the in silico analysis that the mutation renders the MRPS7 protein highly unstable ( Fig. 2A) . The reduced MRPS7 level was accompanied by markedly reduced levels of RC complexes I, III and IV when probed with an OXPHOS subunit antibody cocktail (Fig. 2B ). When mRNA levels were quantified using quantitative PCR (Supplementary Material), results showed significantly reduced MRPS7 mRNA levels in patient fibroblasts (Supplementary Material, Fig. S5 ), suggesting that the MRPS7 mutation induces mRNA instability and consequent reduced protein levels.
In accord with the immunoblot abnormalities, patient fibroblasts showed reduced activities of complexes I and IV when assessed using Mitosciences dipstick assays (Fig. 2C) , having activities of 7.3 and 58.5% of complexes I and IV in controls, respectively (P < 0.01). When the same fibroblast cell lines were permeabilized and forced to maximally produce ATP by supplementing with RC substrates, patient cells were found to have a significantly (P < 0.003) reduced ATP production at ∼80% of the control rate (Fig. 2D ).
MRPS7 mutation causes deficiency in mitochondrial protein synthesis
A mitochondrial protein synthesis assay involving [ into mitochondrial extracts of patient fibroblasts was 54% of that in control cells as determined by densitometry (Fig. 2E) .
Reduced steady-state levels of complex IV subunits (MT-CO1, MT-CO2) were confirmed by immunoblotting of mitochondrial extracts derived from patient fibroblasts (Fig. 2E) . In contrast, steady-state levels of a nuclear-encoded subunit of complex II (70 kDa) were unaffected. These data suggest that the p.Met184-Val MRPS7 mutation leads to a deficiency in mitochondrial protein synthesis, thereby resulting in reduced assembly/expression of RC complexes I, III and IV that contain mitochondrialencoded subunits.
Reduced 12S rRNA and mitochondrial network fragmentation was observed in patient fibroblasts
An unstable small mitochondrial ribosomal subunit results in failure to incorporate the 12S rRNA into the 28 S complex, which renders it labile and it is consequently degraded, whereas the large ribosomal 39 S complex containing 16S rRNA remains unaffected (1, 16) . Quantitative PCR analysis of P1 fibroblast cDNA showed the p.Met184Val MRPS7 mutation results in a significant reduction in 12S rRNA transcript levels with no changes in the abundance of the 16S rRNA (Fig. 3A) . Studies have shown that antibiotic (actinonin) induced loss of 12S rRNA levels (17), a defective mitochondrial protein synthesis machinery or respiratory dysfunction (17) can lead to fragmentation of the mitochondrial network. Mitochondrial labeling of P1 fibroblasts with anti-mitofilin showed mitochondrial network fragmentation (Supplementary Material, Fig. S1 ).
Rescue of deficient RC enzyme activity and 12S rRNA transcripts in patient fibroblasts by wild-type MRPS7
To confirm that the MRPS7 mutation was responsible for the observed clinical and biochemical phenotypes, we performed lentiviral rescue experiments. Transduction of P1 fibroblasts with wild-type and mutant MRPS7 showed increased MRPS7 levels in patient fibroblasts on immunoblot following transduction ( Fig. 2A) . Transduction of the wild-type MRPS7 into patient fibroblasts led to the restoration of complexes I and IV enzyme activity from 7 to 146% (P < 0.01) and 59 to 136% (P < 0.01) of control complexes I and IV values, respectively (Fig. 3B) . No significant rescue was observed in complexes I and IV enzyme activity on transduction with the mutant protein. Transduction of control fibroblast with wild-type MRPS7 also showed high increase in complex I activity; this is perhaps due to the increased level of MRPS7 protein expression. However, there was no increased activity of complex I activity in the control on transduction with a control vector, confirming that the rescue is not a side effect of transduction. Quantitative PCR data showed a partial restoration of the 12S rRNA content in WT MRPS7-transduced P1 fibroblast samples from 36 to 52% of control values (P < 0.05) (Fig. 3C) . On the other hand, transduction with the mutant MRPS7 cDNA did not rescue 12S rRNA levels in P1 fibroblasts.
Discussion
The patients reported on here are siblings presenting with congenital sensorineural deafness and significant hepatic and renal impairment. The siblings also had lactic acidemia and combined RC enzyme deficiencies; however, the older sibling had a more severe clinical progression of the disease, with liver and renal failure unfortunately resulting in death. We report here a c.550A>G, p.Met184Val mutation in the gene MRPS7 that was identified using WES as the cause of the clinical presentations in the affected siblings. Human MRPS7 is a 242 amino acid subunit of the small mitochondrial ribosome, which enhances the binding of neighboring subunits, and is the only primary RNA-binding protein in the 12S rRNA region of the crystal structure of the small mitochondrial ribosome.
In silico modeling of the MRPS7 protein predicted that the p.Met184Val mutation destabilizes the protein tertiary structure and consequently its RNA-binding ability. Studies on the effect of mutations in MRPS16 and MRPS22 showed that they not only result in reduced levels of their respective proteins, but also disrupt the assembly of the entire mitochondrial ribosome small subunit (1,2) and result in a significant reduction in the levels of the 12S rRNA transcript (7, 9) . Similar effects were observed as result of the MRPS7 p.Met184Val mutation where 12S rRNA transcript levels in patient fibroblasts were reduced. Marked reduction in MRPS7 mRNA levels and undetectable MRPS7 protein levels in patient fibroblasts highlight the deleterious effect of the mutation.
The small mitochondrial ribosome, of which MRPS7 is a part, is involved in mitochondrial protein synthesis (5, 18) . Hence the destabilizing effect of the p.Met184Val MRPS7 mutation was predicted to impact on mitochondrial protein synthesis. This prediction was confirmed by the impairment of mitochondrial translation, and the resulting combined OXPHOS complexes I, III and IV deficiency and reduced ATP production observed in the patient fibroblasts. Rescue studies where the wild-type expression of the MRPS7 cDNA using lentiviral transduction rescued the disease phenotype, indicated by the restoration of OXPHOS complexes I and IV activity, as well as 12S rRNA transcript level, established the MRPS7 defect as the cause of the disease. The p.Met184Val MRPS7 mutation causes lactic acidemia and combined RC deficiencies, like all the small subunit MRP mutations reported to date (7-9), indicating that they contribute substantially to mitochondrial translation deficits.
The phenotypic features of our MRPS7 patients have some distinctions from those with mutations in other components of the 28 S mitochondrial ribosome. This is not unusual in RC defects. For example, mitochondrial protein synthesis defects caused by mutations in mitochondrial aminoacyl-tRNA synthetases result in variable phenotypes, with a range of tissues being affected (19) . Interestingly, abnormalities of renal function as a consequence of the MRPS7 p.Met184Val mutation identified in this study (Supplementary Material, Fig. S2 ), are similar to the effect of the MRPS22 p.Arg170His mutation, which causes renal tubulopathy (8) . Another phenotypic overlap is the sensorineural hearing loss presentation, observed both in our patients with the MRPS7 p.Met184Val mutation and those reported with mutations in MT-RNR1 (OMIM 561000), which encodes the 12S rRNA. However, in the case of MT-RNR1 mutations, hearing loss occurs with a later onset and often as a consequence of exposure to aminoglycoside antibiotics (20) . MT-RNR1 mutations disturb the secondary structure of 12S rRNA, and result in ribosomal malfunction (21, 22) . The two affected siblings described here displayed profound congenital sensorineural deafness, the early onset of which may be a consequence of a more severe effect from the p.Met184Val MRPS7 mutation. This may occur as a result of greatly reduced 12S rRNA transcript levels (Fig. 3B) , as opposed to MT-RNR1 mutations that only affect the structure of the 12S rRNA and not the absolute levels. Another effect of reduced 12S rRNA transcript levels is mitochondrial fragmentation, which was observed in our patients fibroblasts, and although the exact role of individual MRPs in regulating translation is not understood, inhibition of the mitoribosome blocks cell proliferation and in turn results in mitochondrial fragmentation (23, 24) .
The hepatic and renal dysfunction observed in our patients could be specific to the MRPS7 mutation or due to a secondary effect as a consequence of the multiple RC enzyme defects (25) . Renal biopsy results showed the presence of dilated renal tubules with giant mitochondria. These features were quite distinct and unusual (Supplementary Material, Fig. S2 ) and, if observed for other patients with MRPS7 mutations, may aid as a diagnostic feature to help identify patients with mutations in this gene.
It is unclear why these sisters appear to have had such different clinical courses to date. Patient 1 was lost to follow up for a number of years and it could be that during this period, when she was medically unsupervised she could have sustained more severe organ damage than her younger sister who has been carefully followed. It is also possible that the antibiotics used during the course of the final illness in Patient 1 interfered with mitochondrial protein synthesis, but we think this is less likely as her demise occurred a month after her presentation with presumed sepsis. It is also possible that other genetic or environmental modifiers have contributed the phenotypic discrepancies in these sisters, as we have noted in other patients with the same nuclear-encoded mitochondrial defect (26) .
The role of MRPs in the pathogenesis of mitochondrial disorders is becoming better understood, with the identification of new disease genes being more feasible with the advances in next-generation sequencing technologies. Our studies of cultured patient fibroblasts, which showed reduced MRPS7 levels, combined OXPHOS complexes I, III and IV deficiency, impairment of mitochondrial translation and reduced 12S rRNA transcript levels, strongly indicate that the p.Met184Val MRPS7 mutation is pathogenic and responsible for the clinical presentation of congenital sensorineural deafness and hepatic and renal impairment in our patients. This study highlights that MRPS7 is an important component of the mitochondrial ribosome, and plays a role in mitochondrial translation and the appropriate functioning of the OXPHOS system.
Materials and Methods
Whole-exome sequencing
The WES procedure was described previously (27) . Briefly, exonic region capture using Agilent SureSelect Human All Exon kit was followed by paired end sequencing on Illumina HiSeq 2000 machines. We applied default settings of the Illumina workflow to process raw image files for base-calling and to generate raw sequencing read files in FASTQ format. We then employed two independent analysis pipelines to conduct sequencing read alignment, variant calling and variant annotation (Supplementary Material, Table S1 ). In the first pipeline (PL1), we used Burrows-Wheeler alignment to map FASTQ files onto the human reference genome (UCSC hg19) (28) . Subsequently, we applied Genome Analysis Tool Kit (GATK, version 1.4) (29) to call variants, followed by functional annotation with Annovar (30) and SnpEff (31) . In the second pipeline (PL2), we used Short Oligonucleotide Analysis Package (SOAP, version2.21) (32) for alignment to hg19, and SOAPsnp (version 1.05) (33) for SNV detection and GATK (29) for indel calling. Finally in PL2, we annotated variants by BGI's self-developed scripts. Under an autosomal-recessive inheritance, we implemented the steps below to filter mutations in both pipelines PL1 and PL2. We first picked homozygous variants shared by both affected sisters, and discarded variants that were not heterozygous in either of the unaffected parents.
Compound heterozygous mutations were also looked at, given that the parents were non-consanguineous; however, none were detected. Then variants which met any of the following criteria were eliminated: (i) outside of exonic regions, (ii) synonymous changes and (iii) with frequency >0.5% in dbSNP135 (34), 1000 Genomes Project (n = 1092 genotyped samples) (35) , HapMap Project (n = 1301 genotyped samples) (36), NHLBI Exome Sequencing Project (n = 6500 exomes) (http://evs.gs.washington.edu/EVS/), CAG-CHOP (n = 669 exomes) or BGI (n = 1414 control exomes) databases. In the next step, we retained variants predicted as 'conserved' by PhyloP (37), 'deleterious' by PolyPhen (38) and 'damaging' by SIFT (39) . Finally, we took into account biological and clinical relevance of the identified variants (Supplementary Material, Table S2 ).
Bioinformatics analysis to identify an ROH from WES data
VCF files generated from WES were parsed with genotypes (GT) '0/0', '0/1' and '1/1' being converted into B allele frequencies (BAFs) 0, 0.5 and 1, respectively. The filter passed markers were considered in a first round analysis, and all variants were considered in a second round analysis to determine comparability. BAFs were processed into PLINK (40) ped format by converting 0 to 'AA', 0.5 to 'AB' and 1 to 'BB'. PLINK map files were generated for each sample based on the individual set of variants called from GATK.
PLINK was run with default settings to detect large genomic spans of mostly homozygous genotypes termed ROH. PLINK '.hom' output files were then converted into ParseCNV (41) '.rawcnv' input format. To determine which genomic regions had both affected siblings with an overlapping ROH, we ran ParseCNV with option 'maxPInclusion 0.5' to report relatively significant signals P = 0.1 which represents two affected with ROH and no unaffected with an overlapping ROH. A very small-scale 'genetic association' study was performed on both the filter passed and unfiltered variant data sets, with two affected family members as cases and three unaffecteds as controls. The results were reviewed, prioritized and visualized on UCSC genome browser custom tracks. PennCNV (42) was used to generate regional BAF profile figures.
Molecular modeling of human wild-type and mutant MRPS7 protein
The sequence of the wild-type human 28S ribosomal protein S7 (MPRS7) was obtained from the UniProt database (43) (accession number Q9Y2R9). This sequence was taken as the query sequence for similarity search against the Protein Data Bank (PDB) (44) using FASTA (45) at www.ebi.ac.uk in an effort to identify homologous proteins of known structure for use as structure templates for model construction. The trigger factor chaperone structure (PDB ID: 3GTY, Chain S) was chosen as the template for modeling of the human wild-type and the mutant MRPS7 protein, because of its structural similarity and good resolution. Structure-based sequence alignment between the template and the query sequence was generated using MOE software (Molecular Computing Group Inc., version 2011.10) with default parameters. Ten three-dimensional structural models of the query sequence were then created based on this alignment using MODELLER (46) (v9.13), one of the most popular software packages for this purpose. The best model was chosen based on its MODELLER scores and the number of outliers detected by MOE. Finally, the model quality was further evaluated using PRO-CHECK (47) at http://swissmodel.expasy.org/ for stereochemical property assessment and ModFOLD (48) (v4.0) at www.reading. ac.uk for overall quality assessment. The mutant MRPS7 protein sequence was generated by manually changing the Met184 residue to Val in the wild-type sequence and its three-dimensional model was generated using the same method described here.
Model-based computational and bioinformatics analysis
The best structural model of the wild-type MRPS7 protein constructed was subjected to in silico computational and bioinformatics analyses from several perspectives. First, the Protein Contact analysis was performed on the model in MOE in order to identify residues interacting with the Met184 residue; next, the conservation level of its residues was calculated based on phylogenetic analyses using the ConSurf server (49) at http:// consurf.tau.ac.il/; third, the free energy change associated with the stability of the folded protein structure upon the Met184Val mutation was calculated using the Eris server (50) at http://troll. med.unc.edu/eris/login.php, the SDM server (51) at http:// mordred.bioc.cam.ac.uk/sdm/sdm.php and the I-Mutant server (52) at http://gpcr2.biocomp.unibo.it/~emidio/I-Mutant3.0. Each server takes a different approach for free energy calculation. The Eris server uses a physical force field combined with fast side-chain packing and backbone relaxation algorithms to calculate the free energy change upon an amino acid mutation. The SDM method is based on the statistical potential energy derived from environment-specific amino acid substitution frequencies within homologous protein families. And the I-Mutant (v3.0) is a neural-network-based method which uses experimental data to train the Support Vector Machine for prediction. Finally, the potential phenotypic impact of the Met184Val mutation was evaluated based on network analyses using the SuSPect server (53) at www.sbg.bio.ic.ac.uk/suspect. For comparison, the best structural model of the mutant MRPS7 protein was also subjected to the Protein Contact analysis.
RC enzyme spectrophotometric assays
Spectrophotometric determinations of enzyme activity for respiratory chain enzymes I-IV from skeletal muscle and liver biopsies were performed as described previously (54) .
Dipstick enzyme activity assays
Complex I (CoI) and complex IV (CoIV) dipstick activity assays were performed on 20 µg of cleared cell lysates of control and patient fibroblasts before and after lentiviral transduction according to the manufacturer's protocol (Mitosciences). The MS1000 dipstick reader (Abcam) was used for measurement and analysis of Abcam's dipstick products.
Immunoblotting
Immunoblotting of patient and control fibroblast samples was performed as previously described (19) with the following modifications. Membranes were probed with anti-MRPS7 antibody (1:500 dilution) (Sigma), or with anti-OXPHOS (1:500 dilution) (Abcam,) for 2 h at room temperature, and re-probed with antiporin (1:10 000 dilution) (Abcam, NSW) for 1 h. Densitometry was performed as previously described (19) and protein levels were normalized to porin.
ATP production rate assay ATP production rate in control (n = 1) and patient (n = 1) fibroblasts was measured in accordance with the method of Shepherd et al. (55) . Briefly, total cellular protein was measured by the BCA method (Pierce) and cells were resuspended in Cell Suspension buffer at a protein concentration of 1 mg/ml. Maximal cellular ATP production was initiated by mixing cells with substrate buffer and incubating at 37°C for 10 min. Cells at 0 and 10 min incubation were then quenched with boiling Quenching buffer and then further diluted 1:10. ATP concentration was measured using the ATP Bioluminescence Assay Kit CLS II (Roche Diagnostics) according to the manufacturer's instructions. ATP production rate is expressed as µmol ATP/min/mg of protein. Triplicate experimental assays were performed.
Mitochondrial protein synthesis assay
Mitochondrial protein synthesis was assayed in fibroblasts as previously described (56) . Samples were analyzed on precast 10% Tricine gels (Life Technologies).
Determination of mitochondrial 12S rRNA and 16S rRNA levels
Total RNA extracted from fibroblasts was converted to cDNA using Superscript III (Invitrogen, Mulgrave, VIC, Australia), following the manufacturer's instructions, with each reaction containing 200 ng of total RNA and 250 ng of random decamers, 200 U of Superscript III and 40 U of RNaseOUT™ (Life Technologies). Full-length cDNA was generated by incubation at 50°C for 60 min. DNA was amplified from 2 μl of human cDNA or 30-70 ng DNA ( plasmids generated for standard curve) with 1 U of Immolase™ DNA Polymerase (Bioline), with a final concentration of 1.5 m MgCl 2 , 500 pM of each primer, 2% (v/v) DMSO, 1  betaine and 1× concentration SYBR green dye (Life Technologies). The cycling conditions were: 95°C for 10 min (95°C for 15 s, 60°C for 15 s, 72°C for 20 s) × 35 cycles.
ACTB (β-actin) served as an endogenous control and MT-RNR1, which encodes 12S rRNA, or MT-RNR2, which encodes 16S rRNA, as the target cDNAs ( primer sequences are available on request). Standard curves were generated by amplifying known amounts of pTOPO2.1/ACTB, pTOPO2.1/MT-RNR1 and pTOPO2.1/MT-RNR2 plasmids. MT-RNR1 and MT-RNR2 copy numbers were quantified relative to ACTB to determine the MT-RNR1 and MT-RNR2 transcript levels in the patient and control samples. Data were obtained by averaging three independent experiments with triplicate samples.
Cloning and lentiviral transduction
A recombinant lentiviral construct containing wild-type MRPS7 (iCumate-pLenti-hMRPS7-SV40-GFP Vector) was purchased from Applied Biological Materials. The mutant c.550A>G MRPS7 construct, generated by PCR amplification of patient cDNA, was cloned into iCumate-pLenti-hMRPS7-SV40-GFP Vector using SspI and XbaI restriction sites. Wild-type, mutant and control iCumate-pLenti-SV40-GFP vectors were transfected separately into HEK 293T-cells using calcium phosphate, with equimolar amounts of the packaging vectors pMD2VSVg, pMDLgpRRE and pRSVrev, pRRLsin18, to produce the respective lentiviruses. Control and patient cells were transduced with the wild-type and mutant constructs, and stably transduced cells were established by puromycin (1 ng/µl) selection. Control and patient cells were also transduced with the lentiviral vector carrying an expression control plasmid iCumate-pLenti-SV40-GFP vector. Three independent transductions were performed in triplicate for each lentiviral construct (wild-type and mutant) per cell line (control and patient).
Statistical analyses
Graphpad Prism v.4.0 was used for all statistical analyses. In all graphs, error bars reflect mean ± standard deviation. A P-value of <0.05 was considered to be statistically significant. Statistical analyses were performed using the non-parametric Mann-Whitney U-test.
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5) . Informed consent was obtained from all patients included in the study.
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